Frazier Life Sciences Nets Over $1.1B for Long-Running Public Biotech Fund

Frazier Life Sciences has raised more than $1.1B for its Public Biotech Fund, bringing total capital raised to $2.8B since its launch in 2021. The fund focuses on long-term investments in small- and mid-cap public biotech companies and can also be deployed in later-stage private companies through crossover financings.